REDWOOD CITY, Calif.--(BUSINESS WIRE)--SentreHEART, Inc., the manufacturer of the LARIAT Suture Delivery Device, today announced the election of medical device industry veteran Richard M. Ferrari to its Board of Directors. Mr. Ferrari is currently the Managing Director and Co-Founder of De Novo Ventures and brings a wealth of strategic and operational knowledge.
“Rich is a visionary business leader with more than 35 years of experience in the medical device industry. His successful track record and proven ability to create transformational value in both start-up and public companies will be an incredible asset, as we bring to market innovative solutions for patients with Atrial Fibrillation,” said Russell Seiber, SentreHEART Founder and Chief Executive Officer.
Mr. Ferrari served as CEO of Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters, which was eventually acquired by Boston Scientific Corporation. His most recent success as CEO was with CardioThoracic Systems (CTS) the market leader in disposable instruments and systems for performing minimally invasive, beating heart bypass surgery, which was acquired by Guidant.
During the past 15 years, Mr. Ferrari has also held numerous board positions, including Spinal Modulations, which was acquired by St. Jude Medical and FoxHollow Technologies, which was taken public. Mr. Ferrari holds a BS degree from Ashland University and an MBA from the University of South Florida.
“With the recent FDA approval of the aMAZE trial, SentreHEART may be able to offer patients with persistent atrial fibrillation an exciting new therapy option, with the potential of becoming a new standard of care,” said Mr. Ferrari. “I look forward to working with the Board of Directors and Executive Leadership to bring continued success in product innovation, clinical development and commercialization.”
ABOUT THE aMAZE TRIAL
The aMAZE trial was approved by the U.S. Food and Drug Administration June 22, 2015 and is designed to evaluate the use of the LARIAT device for the ligation, or closure, of the left atrial appendage (LAA) as an adjunctive treatment to ablation in patients with persistent or longstanding persistent atrial fibrillation (AFib).
AFib is an irregular heartbeat, a rapid heartbeat, or a quivering of the upper chambers of the heart, called the atria, due to a malfunction in the heart's electrical system. It is the most common heart rhythm disorder in the United States, affecting more than 3 million people.i By not getting enough oxygen to the body, AFib can lead to heart and valve diseases, sleep apnea, and chronic fatigue. In addition, atrial fibrillation can lead to two potentially life-threatening conditions: stroke and congestive heart failure.
PVI catheter ablation is the standard of care interventional treatment for patients with persistent and longstanding persistent AFib; however, not all electrical activity originates from the pulmonary veins. The LAA has been known to play a role in triggering recurrence of AFib after treatment with PVI catheter ablation,ii and is the source of most stroke-causing blood clots (thrombus) in AFib patients.iii
ABOUT THE LARIAT SUTURE DELIVERY DEVICE
The LARIAT Suture Delivery Device is indicated for suture placement and knot tying in surgical applications where soft tissue is being approximated and/or ligated with a pre-tied polyester suture. SentreHEART received 510(k) clearances for the LARIAT device in 2006, 2009 and 2014. The LARIAT also has CE Mark approval.
SentreHEART is a privately owned medical device company based in Redwood City, CA. Founded in 2005, SentreHEART has developed technology for remote delivery of suture for anatomic structures.
i Waktare JEP. Atrial fibrillation. Circulation. 2002;
ii Tilz, R.R., et al., Catheter ablation of long-standing persistent atrial fibrillation: a lesson from circumferential pulmonary vein isolation. J Cardiovasc Electrophysiol, 2010. 21(10): p.1085-93
iii Manning WJ. Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulation. Clin Cardiol. 1995; 18: 58,114.